Etoposide in Adult Cancer Patients
Etoposide is a topoisomerase II inhibitor with established efficacy across multiple malignancies, most notably germ cell tumors, small cell lung cancer, and gestational trophoblastic disease, administered either intravenously at 100 mg/m² daily for 5 days or orally at 50-100 mg daily for extended schedules.
Primary Indications
Etoposide demonstrates Category 1 evidence in several malignancies:
Germ Cell Tumors (Testicular Cancer)
- Good prognosis disease: 3 cycles of BEP (bleomycin, etoposide 100 mg/m² IV days 1-5, cisplatin 20 mg/m² days 1-5) every 21 days 1, 2
- Intermediate/poor prognosis: 4 cycles of BEP every 21 days 3
- When bleomycin contraindicated: 4 cycles of EP (etoposide 100 mg/m² days 1-5, cisplatin 20 mg/m² days 1-5) every 21 days 3
- Salvage therapy: VIP regimen (etoposide 75 mg/m² days 1-5, ifosfamide 1200 mg/m² days 1-5, cisplatin 20 mg/m² days 1-5) 1, 2
Small Cell Lung Cancer
- Limited-stage: Cisplatin 20 mg/m² days 1-5 plus etoposide 100 mg/m² days 1-5 every 21 days with concurrent thoracic radiation 4, 5
- Extensive-stage: Same regimen, typically 4-6 cycles 5
- Alternative: Carboplatin AUC 5-6 plus etoposide 100 mg/m² days 1-3 every 21 days when cisplatin contraindicated 5
Ovarian Germ Cell Tumors
- BEP regimen: Etoposide 100 mg/m² days 1-5, cisplatin 20 mg/m² days 1-5, bleomycin 30 units weekly 6
- Good risk: 3 cycles; Poor risk: 4 cycles 6
Gestational Trophoblastic Disease
- High-risk GTN: EMA/CO regimen with etoposide 100 mg/m² IV days 1-2 alternating weekly with cyclophosphamide/vincristine 7
Dosing Schedules
Intravenous Administration
Standard regimens vary by indication but follow these patterns:
- 5-day schedule: 100 mg/m² IV over 30-60 minutes daily for 5 consecutive days, repeated every 21 days 2
- 3-day schedule: 165 mg/m² IV days 1-3 (equivalent efficacy to 5-day but increased long-term toxicity with 4 cycles) 3
- High-dose regimens: 400-750 mg/m² with stem cell support for salvage therapy 2
Oral Administration
Oral etoposide has approximately 50% bioavailability, which decreases with doses >200 mg/day 8, 9:
- Extended schedule: 50-100 mg daily for 14-21 days to maintain continuous topoisomerase II inhibition 8, 9
- Conventional: 200 mg/day for 5 days (though bioavailability is reduced at this dose) 8
- Therapeutic drug monitoring recommended: Target C24,trough <0.3 mg/L and peak concentrations 3-5 mg/L to avoid severe toxicity 9
Dose Adjustments
Renal Impairment
Dose reduction is mandatory for renal dysfunction 10, 11:
| Creatinine Clearance | Dose Adjustment |
|---|---|
| >50 mL/min | 100% of dose |
| 15-50 mL/min | 75% of dose |
| <15 mL/min | Further reduction required (specific data unavailable; consider 50% dose with close monitoring) |
Critical pitfall: Approximately 2% of cisplatin prescriptions and 1.5% of etoposide prescriptions are given without appropriate dose reduction despite renal impairment 12. Always calculate creatinine clearance before each cycle.
Hepatic Impairment
The evidence for hepatic dose adjustment is conflicting and requires nuanced interpretation:
- FDA label recommendation 10, 11: Consider dose reduction in hepatic dysfunction, though specific guidelines not provided
- Clinical pharmacokinetic data 13, 14: Patients with mild-moderate hepatic dysfunction (including HCC with cirrhosis) showed normal etoposide clearance and protein binding, even with bilirubin >1.2 mg/dL
- Practical approach:
- Mild-moderate dysfunction (bilirubin <3 mg/dL, albumin >3 g/dL): No dose reduction necessary with close hematologic monitoring 13
- Severe dysfunction (bilirubin >3 mg/dL): Consider 50-75% dose reduction with therapeutic drug monitoring 14
- Hypoalbuminemia (<3 g/dL): Increased risk of toxicity due to reduced protein binding; consider 25% dose reduction 10, 11
Important caveat: The single case of severe (grade 4) hematological toxicity in hepatic dysfunction studies occurred in a patient with reduced glomerular filtration, not hepatic impairment 13.
Contraindications
Absolute contraindications 10, 11:
- Hypersensitivity to etoposide or polysorbate 80
- Severe bone marrow suppression (neutrophils <500/mm³, platelets <50,000/mm³)
Relative contraindications requiring dose modification:
- Creatinine clearance <50 mL/min
- Hypoalbuminemia (<3 g/dL)
- Prior severe hypersensitivity reactions
Special population warnings:
- Premature infants: Life-threatening syndrome associated with polysorbate 80 component 10, 11
- Pregnancy: Category D—teratogenic effects documented 10, 11
Monitoring Requirements
Before Each Cycle
- Complete blood count with differential (mandatory) 10, 11
- Serum creatinine and calculated creatinine clearance 10, 11
- Liver function tests (bilirubin, transaminases, albumin)
- Performance status assessment
During Treatment
- CBC monitoring: At minimum before each dose; more frequently if neutropenia develops 10, 11
- Infusion monitoring: Observe for hypersensitivity reactions (occurs in 0.7-2% of patients, higher in pediatrics) 10, 11
- Cycle timing: Maintain 21-22 day intervals without dose reductions when possible 3
Criteria for Delaying Treatment
Postpone chemotherapy (maximum 3 days) if 3:
- Fever present
- Neutrophils <500/mm³
- Platelets <100,000/mm³
Growth Factor Support
- Not routinely indicated for prophylaxis 3
- Recommended if serious infectious complications occurred in prior cycle 3
- Consider if prolonged neutropenia threatens dose intensity 3
Key Clinical Pearls
Schedule dependency is critical: Once-daily dosing for 5-8 days produces superior results compared to intermittent administration due to etoposide's phase-specific cytotoxicity in late S and G2 phases 8.
Oral bioavailability is non-linear: Doses >200 mg/day show decreased absorption; split doses or use lower daily doses for extended periods to optimize exposure 8, 9.
Protein binding matters: 93% protein-bound; hypoalbuminemia increases free drug exposure and toxicity risk 10, 11, 13.
Drug interactions: High-dose cyclosporine (>2000 ng/mL) increases etoposide exposure by 80% 10, 11.